MOH Arranges Centralized Drug Purchase Work
This article was originally published in PharmAsia News
At a working meeting for national centralized drug purchase, Ministry of Health Deputy Minister Gao Qiang pointed out that such a system is the objective requirement of deepening the health care system reform and plays an important role. Centralized purchase will: improve the channels for ensuring drug supply as a centralized tender and competitive bidding process can increase drug purchase efficiency and effective supervision of unreasonable pricing; facilitate the establishment of a reasonable drug-price formulation mechanism; and promote pharmaceutical industry optimization and upgrades. Drug companies may redeploy marketing resources in good product development, quality enhancement and competitive building. (Click here for more - Chinese Language)
You may also be interested in...
Executives On The Move: BMS Taps Barclays Exec For Strategy Spot, Epizyme Selects Science Chief And A Board Election At ADC Therapeutics
Bristol-Myers Squibb taps Barclays chair of global life sciences as it EVP, strategy and business development, and cancer therapeutics firm Epizyme Inc. selects a chief scientific officer. At ADC Therapeutics, an oncology drug development company, a new chairman is elected.
Non-CE-marked products on the EU market, virtual notified body audits, free standards and the Commission bid to pause the MDR. March has seen unprecedented developments as COVID-19 has railroaded through the sector decimating regulatory rules and plans.